Vivos Therapeutics (VVOS) stock gains as company receives FDA clearance for its DNA appliance to treat obstructive sleep ...
On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, ...
Vivos Therapeutics shares are trading lower by 25% Thursday morning. The company announced a $4.3 million registered offering ...
LITTLETON, Colo., Sept. 19, 2024 (GLOBE NEWSWIRE) --. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization ...
Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing ...
In recent trading, Vivos Therapeutics Inc (VVOS) stock price has shown some volatility, fluctuating 4.41% over the last five trades and 8.57% over the past 30 trades. This represents a notable shift ...
LITTLETON, Colo., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and ...
Vivos Therapeutics is a pioneering medical device and technology company focused on addressing sleep-related breathing disorders (SRBDs), particularly obstructive sleep apnea (OSA). Their flagship ...
Vivos Therapeutics shares surged 47.50% to close at $4.13, after hitting an intraday high of $5.95 and a low of $3.02. The ...
Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related ...
Vivos Therapeutics shares dropped Thursday after the company said it is offering 1.4 million common shares at $3.15 per share in a registered direct offering. Shares were down 27% to $3.03 in recent ...